• Please log in or register to access this feature.
You have full text access to this OnlineOpen article

Prophylactic lamivudine prevents hepatitis B reactivation in chemotherapy patients

  1. L. L. Lim1,
  2. C. T. Wai1,
  3. Y. M. Lee1,
  4. H. L. Kong2,
  5. R. Lim2,
  6. E. Koay3,
  7. S. G. Lim1

Article first published online: 17 OCT 2002

DOI: 10.1046/j.1365-2036.2002.01364.x

Issue

Alimentary Pharmacology & Therapeutics

Alimentary Pharmacology & Therapeutics

Volume 16, Issue 11, pages 1939–1944, November 2002

Additional Information

How to Cite

Lim, L. L., Wai, C. T., Lee, Y. M., Kong, H. L., Lim, R., Koay, E. and Lim, S. G. (2002), Prophylactic lamivudine prevents hepatitis B reactivation in chemotherapy patients. Alimentary Pharmacology & Therapeutics, 16: 1939–1944. doi: 10.1046/j.1365-2036.2002.01364.x

Author Information

  1. 1

    Departments of Medicine and

  2. 2

    Hematology-Oncology and

  3. 3

    Molecular Diagnosis Center, National University Hospital, Singapore

*Correspondence to: Dr S. G. Lim, Department of Medicine, National University Hospital, 5 Lower Kent Ridge Road, Singapore 119074. E-mail: mdclimsg@leonis.nus.edu.sg

Publication History

  1. Issue published online: 17 OCT 2002
  2. Article first published online: 17 OCT 2002
  3. Accepted for publication 2 August 2002

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (63K)

References

  • 1
    Chu CM. Natural history of chronic hepatitis B virus infection in adults with emphasis on the occurrence of cirrhosis and hepatocellular carcinoma. J Gastroenterol Hepatol 2000; 15: E25–30.
    Direct Link:
  • 2
    Lok ASF, Liang RHS, Chiu EKW, Wong KL, Chan TK, Todd D. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy: report of a prospective study. Gastroenterology 1991; 100: 182–8.
  • 3
    Nakamura Y, Motokura T, Fujita A, Yamashita T, Ogata E. Severe hepatitis related to chemotherapy in hepatitis B virus carriers with hematologic malignancies. Cancer 1996; 78: 2210–5.
    Direct Link:
  • 4
    Markovic S, Drozina G, Vovk M, Fidler-Jenko M. Reactivation of hepatitis B but not hepatitis C in patients with malignant lymphoma and immunosuppressive therapy. A prospective study in 305 patients. Hepato-Gastroenterol 1999; 46: 2925–30.
  • 5
    Kumagai K, Takagi T, Nakamura S, et al. Hepatitis B virus carriers in the treatment of malignant lymphoma: an epidemiological study in Japan. Ann Oncol 1997; 8: S107–9.
  • 6
    Lau JYN, Lai CL, Lin HJ, et al. Fatal reactivation of chronic hepatitis B virus infection following withdrawal of chemotherapy in lymphoma patients. Q J Med 1989; 73: 911–7.
  • 7
    Lok ASF, Lai CL. Acute exacerbations in Chinese patients with chronic hepatitis B virus (HBV) infection. Incidence, predisposing factors and etiology. J Hepatol 1990; 10: 29–34.
  • 8
    Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995; 333: 1657–61.
  • 9
    Yeo W, Chan PKH, Zhong S, et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 2000; 62: 299–307.
    Direct Link:
  • 10
    Yeo W, Steinberg JL, Tam JS, et al. Lamivudine in the treatment of hepatitis B virus reactivation during cytotoxic chemotherapy. J Med Virol 1999; 59: 263–9.
    Direct Link:
  • 11
    Lai CL, Ching CK, Tung AKM, et al. Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: a placebo-controlled trial. Hepatology 1997; 25: 241–4.
    Direct Link:
View Full Article (HTML) Get PDF (63K)